| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |